Evidence map›Paper›PMID 30937406›Full record

ArticleHeliyon2019

Corrigendum to "Targeting B7-H1 (PD-L1) sensitizes cancer cells to chemotherapy" [Heliyon 4 (12) (December 2018) e01039].

Xiaosheng Wu, Yanli Li, Xin Liu, Chunhua Chen, Susan M Harrington, Siyu Cao, Tiancheng Xie, Tu Pham, Aaron S Mansfield, Yiyi Yan and 4 more

Open access · goldAbstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Heliyon, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 1 country.

Xiaosheng WuDepartment of Medicine Division of Hematology, Mayo Clinic College of Medicine, Rochester, MN, USA.
Yanli LiDepartment of Urology, Mayo Clinic College of Medicine, Rochester, MN, USA.
Xin LiuDepartment of Urology, Mayo Clinic College of Medicine, Rochester, MN, USA.
Chunhua ChenDepartment of Biochemistry and Molecular Biology, Mayo Clinic College of Medicine, Rochester, MN, USA.
Susan M HarringtonDepartment of Urology, Mayo Clinic College of Medicine, Rochester, MN, USA.
Siyu CaoDepartment of Urology, Mayo Clinic College of Medicine, Rochester, MN, USA.
Tiancheng XieDepartment of Urology, Mayo Clinic College of Medicine, Rochester, MN, USA.
Tu PhamDepartment of Immunology, Mayo Clinic College of Medicine, Rochester, MN, USA.
Aaron S MansfieldDivision of Medical Oncology, Mayo Clinic College of Medicine, Rochester, MN, USA.
Yiyi YanDivision of Medical Oncology, Mayo Clinic College of Medicine, Rochester, MN, USA.
Eugene D KwonDepartment of Urology, Mayo Clinic College of Medicine, Rochester, MN, USA.
Liewei WangDepartment of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic College of Medicine, Rochester, MN, USA.
Kun LingDepartment of Biochemistry and Molecular Biology, Mayo Clinic College of Medicine, Rochester, MN, USA.
Haidong DongDepartment of Urology, Mayo Clinic College of Medicine, Rochester, MN, USA.
Mayo Clinic · USMayo Clinic in Arizona · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

[This corrects the article DOI: 10.1016/j.heliyon.2018.e01039.].

Identifiers

PMID30937406
PMCPMC6426698
OpenAlexW2922685005

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.